Our top pick for
Evolent Health Inc is a health information services business based in the US. Evolent Health shares (EVH) are listed on the NYSE and all prices are listed in US Dollars. Evolent Health employs 2,900 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$29.52|
|52-week range||$9.44 - $34.60|
|50-day moving average||$28.05|
|200-day moving average||$22.80|
|Wall St. target price||$30.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.83|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-1.37%|
|1 month (2021-09-22)||12.84%|
|3 months (2021-07-22)||36.92%|
|6 months (2021-04-22)||46.43%|
|1 year (2020-10-21)||174.09%|
|2 years (2019-10-21)||291.51%|
|3 years (2018-10-19)||23.67%|
|5 years (2016-10-21)||27.08%|
Valuing Evolent Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Evolent Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Evolent Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.7 million.
The EBITDA is a measure of a Evolent Health's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1 billion|
|Gross profit TTM||$233.1 million|
|Return on assets TTM||-1.52%|
|Return on equity TTM||-11.74%|
|Market capitalisation||$2.7 billion|
TTM: trailing 12 months
There are currently 9.1 million Evolent Health shares held short by investors – that's known as Evolent Health's "short interest". This figure is 0.5% down from 9.1 million last month.
There are a few different ways that this level of interest in shorting Evolent Health shares can be evaluated.
Evolent Health's "short interest ratio" (SIR) is the quantity of Evolent Health shares currently shorted divided by the average quantity of Evolent Health shares traded daily (recently around 988341.87568157). Evolent Health's SIR currently stands at 9.17. In other words for every 100,000 Evolent Health shares traded daily on the market, roughly 9170 shares are currently held short.
However Evolent Health's short interest can also be evaluated against the total number of Evolent Health shares, or, against the total number of tradable Evolent Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evolent Health's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Evolent Health shares in existence, roughly 100 shares are currently held short) or 0.1297% of the tradable shares (for every 100,000 tradable Evolent Health shares, roughly 130 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Evolent Health.
Find out more about how you can short Evolent Health stock.
We're not expecting Evolent Health to pay a dividend over the next 12 months.
Over the last 12 months, Evolent Health's shares have ranged in value from as little as $9.44 up to $34.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Evolent Health's is 2.1952. This would suggest that Evolent Health's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Evolent Health, Inc. , through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients; population health performance that delivers patient-centric cost effective care; and delivery network alignments. This segment also offers specialty care management solutions that support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation, and specific market dynamics; and comprehensive health plan administrative services that helps providers assemble the complete infrastructure required to operate, manage, and capitalize on a variety of financial and administrative management services. The True Health segment operates a commercial health plan for small and large businesses in New Mexico. Evolent Health, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.